From 1921 to 2021, one hundred years have been glorious, one hundred years have been hard, one hundred years have been magnificent. From the broken mountains and rivers under the gunfire of the imperial powers, to the earth shaking of the founding of new China, to the earth shaking of reform and opening up, and to the historic achievements made since the 18th CPC National Congress, the Communist Party of China has always adhered to its original mission, United and led the people through the difficult and difficult past, walked in the changing present, and moved towards a bright future. The Communist Party of China United and led the people to create the development achievement of "startling the world", and wrote the great legend in the history of human development. China stands in the east of the world with more magnificent posture, and the Chinese nation has ushered in the great leap from standing up, getting rich to becoming strong.

For patients with ulcerative colitis (UC), chronic inflammation is often accompanied by periodic tissue damage and repair process, and eventually leads to the occurrence of colorectal cancer. However, in the process of "damage repair" cycle, there is no clear answer to what kind of changes have taken place in the cellular structure of tissues, and how these changes lead to the occurrence of cancer. Two articles published online today in nature, from different perspectives, analyzed the characteristics of cell mutation and tissue remodeling in intestinal tissues of patients with ulcerative colitis at different stages of development from chronic inflammation to cancer, and then revealed the key genes in the development of enteritis and colorectal cancer.

Recently, the "2021 nucleic acid drug development forum" co sponsored by yimaike and the life and Health Industry Development Management Office of Jiangbei new district, Nanjing was successfully held in Huayi Hotel, the Yangtze River boat, Nanjing. Experts and leaders from the scientific community, relevant policy departments, associations and industry have conducted in-depth discussions on the current hot spots and focus issues of nucleic acid drugs.